Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘Diagnostics Has Been Underestimated’: COVID-19 Testing Drives Roche Diagnostics Q1 Sales

Executive Summary

Roche's diagnostics sales increased 5% to $2.93bn in the first quarter of 2020. Molecular diagnostics was the main growth contributor, driven by demand for COVID-19 tests and automated testing systems.

You may also be interested in...



COVID-19 Testing Boosts Roche Diagnostics Sales In H1

Roche's diagnostics division grew 3% in the first half of 2020 with exploding demand for COVID-19 tests offsetting declines in routine testing.

FDA Grants EUA For Roche’s Coronavirus Antibody Test

The company says the serology test has a specificity of 99.8% and sensitivity of 100%

Roche CEO Criticizes Healthcare Under-Investment

The coronavirus pandemic has not had much impact to date on Roche's operations and first-quarter sales grew nicely. However, CEO Severin Schwan hopes certain countries will learn the lesson about not being prepared.

Related Content

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel